Navigation Links
Malignant tumor or benign cyst?
Date:3/10/2008

The results of a study presented today at the Society of Gynecologic Oncologys 39th Annual Meeting on Womens Cancer offer a promising development on the path toward better management of ovarian cancer. Researchers say testing women suspected of having ovarian cancer for a combination of proteins, or biomarkers in the blood called HE4 and CA 125, could be the key to predicting a womans risk for the disease dubbed the silent killer. Currently there is no adequate diagnostic test for ovarian cancer.

Roughly 20 percent of women will be diagnosed with an ovarian cyst or tumor at some point in their life, and only a small percentage of these women will be diagnosed with ovarian cancer, said Lead Researcher Richard Moore, M.D., assistant professor at The Warren Alpert Medical School of Brown University and a gynecologic oncologist in the Program in Womens Oncology at Women & Infants Hospital of Rhode Island. The problem is that current methods for distinguishing benign ovarian tumors from malignant ones are limited and as a result, women must undergo surgery without an accurate assessment as to their risk for having ovarian cancer prior to their surgery.

Dr. Moore notes that fewer than half of all ovarian cancer patients have their initial surgery performed by a gynecologic oncologist or surgeon with specialized training in the management of ovarian cancer. Our research is aimed at identifying patients at high risk for harboring an ovarian cancer so that they receive the right care from the right physician.

Currently, CA 125 is the only blood test that can be used to help predict a womans risk for ovarian cancer and to help with the clinical management of the disease. However, CA 125 alone lacks the sensitivity required for the detection of ovarian cancer prompting researchers to look at the ability of combinations of biomarkers to predict the presence of ovarian cancer. Earlier this year, Dr. Moore published results of a pilot study in the journal of Gynecologic Oncology evaluating nine potential biomarkers and the ability of multiple marker combinations to predict the risk for ovarian cancer in women. His findings showed the combination of HE4 and CA 125 provided the highest level sensitivity and specificity out of all marker combinations for predicting the presence of ovarian cancer.

In a prospective, double-blinded, multicenter clinical trial, Dr. Moore and his team studied 496 women presenting with pelvic mass or ovarian cysts to determine if tests targeting multiple markers utilizing HE4 and CA 125 and a predictive algorithm could accurately assess the risk for epithelial ovarian cancer prior to surgery. Researchers measured levels of the biomarkers within the womens blood and then compared the results with biopsies of their tumors. The combination of biomarkers performed well in both pre- and post-menopausal women, accurately stratifying 95 percent of patients with epithelial cancer as high risk and 75 percent of benign cases as low risk.

Studies suggest women with ovarian cancer have better outcomes and increased survival when treated by surgeons trained in the management of ovarian cancer and at institutions specializing in the care of women with this disease, adds Dr. Moore. By using the combination of HE4 and CA 125 as a model to assess a womens risk for ovarian cancer, physicians can better triage patients for care and refer them to the appropriate specialist whether at a community hospital or large academic institution.

Together, HE4 and CA 125 offer a powerful combination that could dramatically change the way ovarian cancer is managed at all stages of care, said Dr. Olle Nilsson, vice president and chief scientific officer of Fujirebio Diagnostics, the developers of the CA 125 test. As research continues to progress, it is our hope that a test for HE4 and CA 125 could eventually lead to a plausible screening tool.

Fujirebio Diagnostics has developed a manual test for HE4 and will be developing automated formats of the test for Fujirebio instruments. The HE4 test is CE marked in Europe. The company has applied to the U.S. Food and Drug Administration (FDA) and hopes to see availability of the test in late 2008.


'/>"/>

Contact: Stephanie Euler
stephanie@sternassociates.com
908-276-4344 x213
Fujirebio Diagnostics
Source:Eurekalert

Related medicine news :

1. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
2. iNOS expression may links chronic biliary inflammation to malignant transformation
3. Protein in embryonic stem cells control malignant tumor cells
4. Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells
5. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
6. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
7. Study details regulation of vital tumor suppressor gene p53
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Customized virus kills brain tumor stem cells that drive lethal cancer
10. Study suggests brain tumors need treatment with multiple targeted drugs
11. Bright tumors, dim prospects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... Trinity Health today launched its inaugural ... aimed at improving care and reducing readmission rates for patients who are dually ... Health is to drive innovation that transforms our ministry and our industry to ...
(Date:5/4/2016)... SCOTTSDALE, AZ (PRWEB) , ... May 04, 2016 ... ... 2016 Annual Technology & Business Conference. The conference opened on Tuesday with Frank ... panel discussion on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model ...
(Date:5/4/2016)... ... ... Level 10 Head Over Heels Athletic Arts’ gymnast Alessandra Brovedani -- who goes ... fall of 2019. , After a handful of college visits, the Berkeley High ... her connection with the coaching staff and the excitement surrounding Wildcat Athletics. , “What ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... therapy products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... hip replacement patients. The plush design enhances comfort and enables the patient to ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Nike Rugby Camp's ... rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike Camp ... players every year since 2009. , “I’m excited for our eighth summer here ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... May 3, 2016  Forté Elements, LLC (Forté) is excited to announce the launch ... address the nutritional needs of recovery for a variety of clinical conditions. Founded in ... Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)...  Deerfield announced today it led the $44.5 ... Graybug Vision is an early stage pharmaceutical company ... for ocular diseases including wet age-related macular degeneration ... developed at Johns Hopkins University and has been ... Graybug Vision is developing ophthalmology products enabling ...
Breaking Medicine Technology: